Advagene Biopharma Co., Ltd. (TPEX: 6709)
Health Care · Pharmaceuticals · TW
NT$25.15
+1.00% today · +8.4% 1Y
Advagene Biopharma Co., Ltd. (TPEX: 6709) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $46.90M and employs 16 people.
Over the last twelve months the share price has gained 8.4%, trading between 21.90 and 41.00.
Tweenvest scores Advagene Biopharma Co., Ltd. across four factors: quality 27/100. Its strongest factor is quality.
6709 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $46.90M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.51
- Dividend yield
- —
- Beta (5Y)
- 0.66
- 52-week high
- NT$41.00
- 52-week low
- NT$21.90
- Avg volume (3M)
- —
- Shares outstanding
- 59.38M
- Employees
- 16
- Next earnings
- —
About Advagene Biopharma Co., Ltd.
Based in Taipei, Taiwan, Advagene Biopharma Co., Ltd. is a firm dedicated to pioneering advancements in vaccine science and associated medical solutions. Its current development portfolio comprises a nasal spray vaccine for influenza, various allergy-specific vaccines, and an immunotherapy targeting COVID-19.
- ISIN
- TW0006709009
- Founded
- 2006
- Listed since
- Nov 29, 2018
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,211.90 | -1.76% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $271.30 | -0.67% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $154.34 | -1.35% |
| Roche Holding AGSWX: ROP | $371.62B | CHF369.90 | -1.04% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.60 | -1.73% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.27 | -1.05% |
Figures last refreshed Aug 18, 2026.